# Endocrinology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN-TD
- Date: 1953-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celia Montrose-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Rupert Hallam, MD

## Reason for consultation

Bilateral tender gynecomastia, suppressed testosterone and gonadotropins, and low libido in a 40-year-old man three weeks after the last of a year of high-dose estrogen injections given without his free consent. Please confirm the cause, advise what further tests are needed, and advise on recovery, testosterone therapy, bone health, and surgery. **S**

## History

Mr. Turing is seen at the request of Dr. Hallam, five weeks after the last of about a year of high-dose estrogen injections that were imposed on him abroad as the alternative to imprisonment. He did not consent freely and will not take them again. Breast enlargement began within a few months of the injections and became tender; libido and erections were lost over the same months. He has no testicular pain or swelling, nipple discharge, headache, visual disturbance, or galactorrhea. He has never used anabolic steroids, androgens, or other drugs linked to gynecomastia and has no liver, kidney, or thyroid disease. He has had no leg swelling, chest pain, or breathlessness. He runs 20 to 40 km a week. His sexual orientation was discussed only as he chose; it has no bearing on these findings. He asked for each step of the examination to be explained, and agreed to each. **S**

## Examination

| System | Finding |
|---|---|
| General | Tall, lean man; normal male hair distribution |
| Breast | Examined with his agreement: firm, tender, rubbery, symmetric glandular tissue about 4 cm across behind each nipple; no discrete or eccentric mass, skin change, nipple discharge, or axillary nodes |
| Genitourinary | Examined with his agreement: testes soft and slightly small without masses, as the ultrasound confirms |
| Neck | No thyroid enlargement |

BP 120/74 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 71 kg; BMI 22.4 kg/m². All vital signs are synthetic.

## Data reviewed

The intake results, today's estradiol of 46 pg/mL and LH of 0.9 mIU/mL, and today's scrotal ultrasound, which shows testes of about 15 mL each, homogeneous, with no mass and no varicocele. PHQ-9: 14; Estradiol: 46 pg/mL (high); LH: 0.9 m[IU]/mL (low). All results are synthetic.

## Assessment

1. **Bilateral gynecomastia** (N62). True gynecomastia, typical on examination and fully explained by a year of high-dose exogenous estrogen. hCG and AFP are normal and the scrotal ultrasound shows no mass, so a testicular tumor is excluded; liver, kidney, and thyroid disease are excluded. Breast imaging is not needed because the examination is typical and shows no discrete mass. Most gynecomastia of recent onset regresses once the cause is removed, though tissue present for many months may become fibrous and persist. **S**
2. **Drug-induced hypogonadotropic hypogonadism** (E23.1). Suppression of LH, FSH, and testosterone by exogenous estrogen, with estradiol already falling. Recovery is expected over two to six months. Testosterone therapy would suppress the axis again and is not indicated for a transient, drug-induced deficiency. Tamoxifen and aromatase inhibitors are not justified in general and are not needed here. The mildly raised prolactin is an expected estrogen effect and should be rechecked after the estrogen clears; no pituitary imaging is needed unless it stays raised. **S**
3. **Adverse effects of high-dose estrogen given without free consent** (T38.5X5A). An iatrogenic harm. He has no symptoms or signs of venous thrombosis, and his liver tests are normal. The treatment had no medical indication. **S**
4. **Vitamin D insufficiency** (E55.9). Appropriate to replace while testosterone is low. **S**

## Recommendations

1. No further estrogen; watchful waiting for the gynecomastia.
2. No testosterone therapy, tamoxifen, or aromatase inhibitor while the axis recovers.
3. Testosterone, estradiol, LH, FSH, prolactin, and hemoglobin about six weeks from now, then every six to eight weeks until normal; testosterone and estradiol once more at about six months.
4. Continue cholecalciferol 1,000 units daily, calcium from food, and running with strength work; a bone density scan only if hypogonadism persists beyond six months or a fragility fracture occurs.
5. Breast imaging only if the examination becomes equivocal or a discrete mass appears.
6. A plastic surgery opinion if the gynecomastia persists about twelve months after the estrogen stopped and he wants it removed.
7. Return to endocrinology if testosterone remains low or LH and FSH have not recovered six months after the last dose, or if prolactin stays raised.

## Strengths and supports

- Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home **S**

## Communication

Discussed with Dr. Hallam the same day; Mr. Turing agrees with the plan and has a written copy. **S**

## Follow-up

Primary care monitors recovery. Endocrinology is available for review on the criteria above. **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012), Endocrine Society
